

1642

P#11

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900



1600

RAW SEQUENCE LISTING

DATE: 07/30/2002

PATENT APPLICATION: US/09/615,624A

TIME: 15:08:40

Input Set : A:\734sl.txt

Output Set: N:\CRF3\07302002\I615624A.raw

ENTERED

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900

4 <110> APPLICANT: University of Southern California
5 Brooks, Peter C.
6 Rodriguez, Dorothy
8 <120> TITLE OF INVENTION: NOVEL METHOD AND COMPOSITION FOR
9 INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9
10 AND BETA 1 INTEGRINS
12 <130> FILE REFERENCE: 13761-734
14 <140> CURRENT APPLICATION NUMBER: US 09/615,624A
15 <141> CURRENT FILING DATE: 2000-07-13
17 <150> PRIOR APPLICATION NUMBER: US 60/143,581
18 <151> PRIOR FILING DATE: 1999-07-13
20 <150> PRIOR APPLICATION NUMBER: US 60/152,495
21 <151> PRIOR FILING DATE: 1999-09-02
23 <160> NUMBER OF SEQ ID NOS: 3
25 <170> SOFTWARE: FastSEQ for Windows Version 4.0
27 <210> SEQ ID NO: 1
28 <211> LENGTH: 10
29 <212> TYPE: PRT
30 <213> ORGANISM: Artificial Sequence
32 <220> FEATURE:
33 <223> OTHER INFORMATION: Synthetic sequence, FRIP-1
35 <223> OTHER INFORMATION: Binds to MMP-9 and beta 1 integrins.
W--> 37 <400> 1
38 Cys Arg Leu Arg Ser Gly Glu Pro Gln Cys
39 1 5 10
42 <210> SEQ ID NO: 2
43 <211> LENGTH: 10
44 <212> TYPE: PRT
45 <213> ORGANISM: Artificial Sequence
47 <220> FEATURE:
48 <223> OTHER INFORMATION: Synthetic sequence, AAA
50 <223> OTHER INFORMATION: Binds to MMP-9 and beta 1 integrins with
51 substantially reduced binding capacity compared to
52 the binding capacity of FRIP-1 to MMP-9 and beta 1
53 integrins.
W--> 55 <400> 2
56 Cys Arg Ala Ala Ala Gly Glu Pro Gln Cys
57 1 5 10
60 <210> SEQ ID NO: 3
61 <211> LENGTH: 10
62 <212> TYPE: PRT
63 <213> ORGANISM: Artificial Sequence
65 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 07/30/2002

PATENT APPLICATION: US/09/615,624A

TIME: 15:08:40

Input Set : A:\734sl.txt

Output Set: N:\CRF3\07302002\I615624A.raw

66 <223> OTHER INFORMATION: Synthetic sequence, AAAA
68 <223> OTHER INFORMATION: Binds to MMP-9 and beta 1 integrins with
69 substantially reduced binding capacity compared to
70 the binding capacity of FRIP-1 to MMP-9 and beta 1
71 integrins.

W--> 73 <400> 3

74 Cys Arg Ala Ala Ala Glu Pro Gln Cys

75 1 5 10